Literature DB >> 30732715

Heart Failure With Preserved Ejection Fraction and Diabetes: JACC State-of-the-Art Review.

Kelly McHugh1, Adam D DeVore2, Jingjing Wu3, Roland A Matsouaka3, Gregg C Fonarow4, Paul A Heidenreich5, Clyde W Yancy6, Jennifer B Green7, Natasha Altman8, Adrian F Hernandez9.   

Abstract

Heart failure with preserved ejection fraction (HFpEF) is now the most common form of HF, affecting over 3 million adults in the United States alone. HFpEF is a heterogenous syndrome. One important phenotype may be related to comorbid conditions, including diabetes mellitus (DM). DM has a prevalence of approximately 45% in HFpEF, but characteristics and outcomes of this population are poorly understood. In this review, the authors summarize data from several clinical trials of HFpEF therapeutics and provide original data from a large cohort using the Get With The Guidelines-HF registry, which together suggest that DM is associated with increased morbidity and long-term mortality in HFpEF. The authors then discuss several common pathological mechanisms in HFpEF and DM, including sodium retention, metabolic derangements, impaired skeletal muscle function, and potential therapeutic targets. As the understanding of comorbid HFpEF and DM improves, it is hoped clinicians will be better equipped to offer effective, patient-centered treatments.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  clinical trials; comorbidity; heart failure; registries

Mesh:

Year:  2019        PMID: 30732715     DOI: 10.1016/j.jacc.2018.11.033

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  55 in total

1.  On the search for the right definition of heart failure with preserved ejection fraction.

Authors:  Agnieszka Kapłon-Cieślicka; Karolina Kupczyńska; Piotr Dobrowolski; Błażej Michalski; Miłosz J Jaguszewski; Waldemar Banasiak; Paweł Burchardt; Łukasz Chrzanowski; Szymon Darocha; Justyna Domienik-Karłowicz; Jarosław Drożdż; Marcin Fijałkowski; Krzysztof J Filipiak; Marcin Gruchała; Ewa A Jankowska; Piotr Jankowski; Jarosław D Kasprzak; Wojciech Kosmala; Piotr Lipiec; Przemysław Mitkowski; Katarzyna Mizia-Stec; Piotr Szymański; Agnieszka Tycińska; Wojciech Wańha; Maciej Wybraniec; Adam Witkowski; Piotr Ponikowski; On Behalf Of "Club 30" Of The Polish Cardiac Society
Journal:  Cardiol J       Date:  2020-09-28       Impact factor: 2.737

Review 2.  Lipids: a Potential Molecular Pathway Towards Diastolic Dysfunction in Youth-Onset Type 2 Diabetes.

Authors:  Amy S Shah; Sakthivel Sadayappan; Elaine M Urbina
Journal:  Curr Atheroscler Rep       Date:  2022-01-24       Impact factor: 5.113

Review 3.  Transforming growth factor-β in myocardial disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Nat Rev Cardiol       Date:  2022-01-04       Impact factor: 32.419

4.  Mechanisms of atrial fibrillation in aged rats with heart failure with preserved ejection fraction.

Authors:  Thassio Ricardo Ribeiro Mesquita; Rui Zhang; Geoffrey de Couto; Jackelyn Valle; Lizbeth Sanchez; Russell G Rogers; Kevin Holm; Weixin Liu; Eduardo Marbán; Eugenio Cingolani
Journal:  Heart Rhythm       Date:  2020-02-15       Impact factor: 6.343

5.  Association of Midlife Cardiovascular Risk Factors With the Risk of Heart Failure Subtypes Later in Life.

Authors:  Laura P Cohen; Eric Vittinghoff; Mark J Pletcher; Norrina B Allen; Sanjiv J Shah; John T Wilkins; Patricia P Chang; Chiadi E Ndumele; Anne B Newman; Diane Ives; Mathew S Maurer; Elizabeth C Oelsner; Andrew E Moran; Yiyi Zhang
Journal:  J Card Fail       Date:  2020-11-22       Impact factor: 5.712

Review 6.  Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection fraction.

Authors:  Mouhamed Nashawi; Omar Sheikh; Ayman Battisha; Mahnoor Mir; Robert Chilton
Journal:  Heart Fail Rev       Date:  2022-01       Impact factor: 4.214

7.  Meta-analysis addressing the impact of cardiovascular-acting medication on peak oxygen uptake of patients with HFpEF.

Authors:  Aristi Boulmpou; Marieta P Theodorakopoulou; Maria-Eleni Alexandrou; Afroditi K Boutou; Christodoulos E Papadopoulos; Eva Pella; Pantelis Sarafidis; Vassilios Vassilikos
Journal:  Heart Fail Rev       Date:  2022-01-24       Impact factor: 4.214

Review 8.  Consensus document: management of heart failure in type 2 diabetes mellitus.

Authors:  Upendra Kaul; Saumitra Ray; D Prabhakar; Arun Kochar; Kamal Sharma; Prakash Kumar Hazra; Subhash Chandra; Dharmesh Ramakant Bhai Solanki; Anjan Lal Dutta; Viveka Kumar; M Srinivas Rao; Abraham Oomman; Sameer Dani; Brian Pinto; T R Raghu
Journal:  Heart Fail Rev       Date:  2021-09       Impact factor: 4.214

9.  SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis.

Authors:  Rhanderson Cardoso; Fabrissio P Graffunder; Caique M P Ternes; Amanda Fernandes; Ana V Rocha; Gilson Fernandes; Deepak L Bhatt
Journal:  EClinicalMedicine       Date:  2021-06-05

10.  Negative synergism of diabetes mellitus and obesity in patients with heart failure with preserved ejection fraction: a cardiovascular magnetic resonance study.

Authors:  Selcuk Kucukseymen; Ulf Neisius; Jennifer Rodriguez; Connie W Tsao; Reza Nezafat
Journal:  Int J Cardiovasc Imaging       Date:  2020-06-12       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.